Literature DB >> 28715994

FGF23 and Nutritional Metabolism.

Lindsay R Pool1, Myles Wolf2.   

Abstract

The discovery of fibroblast growth factor 23 (FGF23) has provided a more complete understanding of the regulation of phosphate and mineral homeostasis in health and in chronic kidney disease. It has also offered new insights into stratification of risk of cardiovascular events and death among patients with chronic kidney disease and the general population. In this review, we provide an overview of FGF23 biology and physiology, summarize clinical outcomes that have been associated with FGF23, discuss potential mechanisms for these observations and their public health implications, and explore clinical and population health interventions that aim to reduce FGF23 levels and improve public health.

Entities:  

Keywords:  cardiovascular disease; chronic kidney disease; fibroblast growth factor 23; nutritional metabolism; phosphate

Mesh：

Substances：

Year:  2017        PMID： 28715994     DOI： 10.1146/annurev-nutr-071816-064620

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN： 0199-9885            Impact factor:   11.848


  13 in total

Review 1.  Phosphate, the forgotten mineral in hypertension.

Authors:  Han-Kyul Kim; Masaki Mizuno; Wanpen Vongpatanasin
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

Review 2.  Fibroblast growth factors 19 and 21 in acute liver damage.

Authors:  Zhao Shan; Gloria Alvarez-Sola; Iker Uriarte; María Arechederra; Maite G Fernández-Barrena; Carmen Berasain; Cynthia Ju; Matías A Avila
Journal:  Ann Transl Med       Date:  2018-06

3.  Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD: A Secondary Analysis from a Controlled Diet Balance Study.

Authors:  Elizabeth R Stremke; Linda D McCabe; George P McCabe; Berdine R Martin; Sharon M Moe; Connie M Weaver; Munro Peacock; Kathleen M Hill Gallant
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-19       Impact factor: 8.237

Review 4.  Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment.

Authors:  Vincenzo B Polsinelli; Arjun Sinha; Sanjiv J Shah
Journal:  Curr Heart Fail Rep       Date:  2017-12

5.  Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Authors:  Connor Francis; Guillaume Courbon; Claire Gerber; Samantha Neuburg; Xueyan Wang; Corey Dussold; Maralee Capella; Lixin Qi; Tamara Isakova; Rupal Mehta; Aline Martin; Myles Wolf; Valentin David
Journal:  Kidney Int       Date:  2019-08-30       Impact factor: 10.612

6.  Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial.

Authors:  Vickie S Braithwaite; Martin N Mwangi; Kerry S Jones; Ayşe Y Demir; Ann Prentice; Andrew M Prentice; Pauline E A Andang'o; Hans Verhoef
Journal:  Am J Clin Nutr       Date:  2021-05-08       Impact factor: 7.045

Review 7.  Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.

Authors:  Guillaume Courbon; Marta Martinez-Calle; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 3.416

8.  Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.

Authors:  Ehimare Akhabue; Thanh-Huyen T Vu; Anand Vaidya; Erin D Michos; Ian H de Boer; Bryan Kestenbaum; Matthew Allison; Moyses Szklo; Pamela Ouyang; Clyde W Yancy; Myles Wolf; Tamara Isakova; Mercedes R Carnethon
Journal:  Am J Hypertens       Date:  2019-01-01       Impact factor: 3.080

9.  FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study.

Authors:  Ehimare Akhabue; Samantha Montag; Jared P Reis; Lindsay R Pool; Rupal Mehta; Clyde W Yancy; Lihui Zhao; Myles Wolf; Orlando M Gutierrez; Mercedes R Carnethon; Tamara Isakova
Journal:  Hypertension       Date:  2018-04-30       Impact factor: 9.897

Review 10.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.